Description: OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
Home Page: ostherapies.com
15825 Shady Grove Road
Rockville,
MD
20850
United States
Phone:
410-297-7793
Officers
| Name | Title |
|---|---|
| Mr. Paul A. Romness M.P.H. | Founder, Chairman, President & CEO |
| Dr. Robert G. Petit Ph.D. | Chief Medical Officer & Chief Scientific Officer |
| Mr. Christopher P. Acevedo | Chief Financial Officer |
| Mr. Jack Doll | Chief of Staff |
| Mr. Gerald E. Commissiong | Chief Business Officer |
Exchange: NYSE MKT
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-08-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |